Stay updated with breaking news from Michael Szumera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 -- FibroGen,...
- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to pla
Study did not meet the primary endpointPamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 ... | June 7, 2023
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates ● ... | August 11, 2022
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector...